Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, 646000, China.
BMC Health Serv Res. 2018 Jul 11;18(1):537. doi: 10.1186/s12913-018-3358-5.
BACKGROUND: Proton pump inhibitors (PPIs) remain one of the world's most frequently prescribed medications and there is a growing number of publications on correct versus incorrect use of PPIs worldwide. The objective of this observational retrospective study was to assess changes in PPI prescribing trends over the past decade and pharmacists' effect on optimizing PPI prescribing practice at a tertiary hospital in China. METHODS: We collected the prescriptions of PPIs in our hospital from January 2007 to December 2016. Then the rate of PPI prescribing, the defined daily doses (DDDs) and expenditures were calculated and plotted to show the change in utilization of and expenditure on PPIs. Reasons behind this change and effect of pharmacists' intervention were evaluated by investigating the rationality of PPI use through sample surveys of patients of pre-intervention (Jul.-Dec. 2015) and post-intervention (Jul.-Dec. 2016). RESULTS: In outpatient settings, the rate of PPI prescribing remained almost constant, utilization (from 135,808 DDDs to 722,943 DDDs) and expenditure (from 1.85 million CNY to 7.96 million CNY) increased for the past ten years, dominated by oral formulations and rabeprazole. In contrast, in inpatient settings, the rate of PPI prescribing (from 20.41 to 37.21%), utilization (from 132,329 DDDs to 827,747 DDDs) and expenditure (from 3.15 million CNY to 25.29 million CNY) increased from 2007 to 2015 and then decreased, dominated by injection formulations and omeprazole. Pharmacist interventions could significantly promote the rational use of PPIs (44.00% versus 26.67%), decrease PPI use and reduce patients' charges (P < 0.05). CONCLUSIONS: The utilization of and expenditure on PPIs grew due to the increase of patients and irrational use of PPI. Pharmacist interventions help to reduce PPI utilization and expenditure and enhance rationality for inpatients, but much work should be done to regulate injection and originator formulas, and improve the rationality in the future.
背景:质子泵抑制剂(PPIs)仍然是世界上最常被开的药物之一,全球关于 PPI 正确与错误使用的出版物越来越多。本观察性回顾性研究的目的是评估过去十年中 PPI 开处方趋势的变化,以及药剂师在中国一家三级医院优化 PPI 开处方实践的效果。
方法:我们收集了 2007 年 1 月至 2016 年 12 月我院的 PPI 处方。然后计算 PPI 的开方率、限定日剂量(DDD)和支出,并绘制图表以显示 PPI 的利用和支出的变化。通过对干预前(2015 年 7 月至 12 月)和干预后(2016 年 7 月至 12 月)患者的样本调查,评估这种变化的原因和药剂师干预的效果,以调查 PPI 使用的合理性。
结果:在门诊环境中,PPI 的开方率基本保持不变,过去十年的利用率(从 135808DDD 增加到 722943DDD)和支出(从 185 万人民币增加到 7960 万人民币)增加,主要由口服制剂和雷贝拉唑主导。相比之下,在住院环境中,PPI 的开方率(从 20.41%增加到 37.21%)、利用率(从 132329DDD 增加到 827747DDD)和支出(从 3150 万人民币增加到 2529 万人民币)从 2007 年到 2015 年增加,然后减少,主要由注射制剂和奥美拉唑主导。药剂师的干预可以显著促进 PPI 的合理使用(44.00%比 26.67%),减少 PPI 的使用并降低患者的费用(P<0.05)。
结论:由于患者的增加和 PPI 的不合理使用,PPI 的利用和支出增加。药剂师的干预有助于减少 PPI 的使用和支出,提高住院患者的合理性,但仍需做大量工作来规范注射剂和原研制剂,并在未来提高合理性。
BMC Health Serv Res. 2015-1-22
Int J Clin Pharmacol Ther. 2003-5
Expert Rev Pharmacoecon Outcomes Res. 2010-2
BMC Health Serv Res. 2019-11-21
Fam Pract. 2001-6
Expert Rev Pharmacoecon Outcomes Res. 2013-2
World J Gastroenterol. 2012-6-28
J Pharm Health Care Sci. 2025-8-11
Int J Mol Sci. 2024-11-29
Pharmaceuticals (Basel). 2023-9-30
Eklem Hastalik Cerrahisi. 2017-4
CMAJ. 2017-2-6
Postepy Hig Med Dosw (Online). 2016-10-14
Medicine (Baltimore). 2015-7
BMC Health Serv Res. 2015-1-22
World J Methodol. 2011-9-26